Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. In FY 13 this project included clinical assessments and data analysis for clinical trials of investigational vaccines against four types of infectious diseases: filoviruses (Marburg and Ebola), influenza (avian and seasonal strains), alphaviruses (Chikungunya) and malaria. Further evaluation of vaccine approaches will continue as the VRC develops additional candidate vaccine regimens. Published results from clinical trials have included: an Ebola DNA vaccine study (VRC 204) Clin Vaccine Immunol, 2006. 13(11):1267-77; a West Nile virus DNA vaccine study (VRC 302) J Infect Dis, 2007. 196(12):1732-40, a SARS DNA vaccine study (VRC 301) Vaccine 2008 Nov 25;26(50):6338-43. a second generation West Nile virus DNA vaccine study (VRC 303) J Infect Dis, 2011, May 15;203(10). a second generation Ebola rAd5 vaccine study (VRC 205) Vaccine 2010 Oct 27. an H5N1 gene based prime, inactivated boost study (VRC 306) Lancet Infect Dis. 2011 Dec;11(12):916-24 an H5 DNA vaccine study and H5 route study (VRC 304 and VRC 305) Clin Vaccine Immunol. 2012 Nov;19(11):1792-7 a follow on H5N1 prime, inactivated boost interval examination study (VRC 310) J Infect Dis. 2013 Aug 1;208(3):413-7, J Infect Dis. 2013 Aug 1;208(3):418-22 a dose-escalation with experimental challenge to evaluate intravenous administration of PfSPZ vaccine trial (VRC 312) Science. 2013 Aug 8

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Corti, Davide; Misasi, John; Mulangu, Sabue et al. (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351:1339-42
Dowd, Kimberly A; DeMaso, Christina R; Pelc, Rebecca S et al. (2016) Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep 16:1485-91
Ishizuka, Andrew S; Lyke, Kirsten E; DeZure, Adam et al. (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22:614-23
Ewer, Katie; Rampling, Tommy; Venkatraman, Navin et al. (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374:1635-46
Misasi, John; Gilman, Morgan S A; Kanekiyo, Masaru et al. (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351:1343-6
Ledgerwood, Julie E; Hu, Zonghui; Costner, Pamela et al. (2015) Phase I Clinical Evaluation of Seasonal Influenza Hemagglutinin (HA) DNA Vaccine Prime Followed by Trivalent Influenza Inactivated Vaccine (IIV3) Boost. Contemp Clin Trials :
Ngwuta, Joan O; Chen, Man; Modjarrad, Kayvon et al. (2015) Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162
Crank, Michelle C; Gordon, Ingelise J; Yamshchikov, Galina V et al. (2015) Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One 10:e0123969
Ledgerwood, Julie E; Bellamy, Abbie R; Belshe, Robert et al. (2015) DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One 10:e0125914
Ledgerwood, Julie E; Sullivan, Nancy J; Graham, Barney S (2015) Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med 373:776

Showing the most recent 10 out of 34 publications